[HTML][HTML] Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
JL Su, AM Malfait - Osteoarthritis and cartilage, 2015 - Elsevier
Summary Objective/Method Aggrecanase activity, most notably ADAMTS-5, is implicated in
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
J Larkin, TA Lohr, L Elefante… - Osteoarthritis and …, 2015 - pubmed.ncbi.nlm.nih.gov
Objective/method Aggrecanase activity, most notably ADAMTS-5, is implicated in
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.
J Larkin, TA Lohr, L Elefante, J Shearin… - Osteoarthritis and …, 2015 - europepmc.org
Results Structural mapping predicts the most potent mAbs employ a unique mode of
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …
[引用][C] Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
J Larkin, TA Lohr, L Elefante, J Shearin… - Osteoarthritis and …, 2015 - cir.nii.ac.jp
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[HTML][HTML] Translational Development of an ADAMTS-5 Antibody for Osteoarthritis Disease Modification
J Larkin, TA Lohr, L Elefante, J Shearin… - … and cartilage/OARS …, 2015 - ncbi.nlm.nih.gov
Results Structural mapping predicts the most potent mAbs employ a unique mode of
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
J Larkin, TA Lohr, L Elefante, J Shearin… - Osteoarthritis and …, 2015 - infona.pl
Aggrecanase activity, most notably ADAMTS-5, is implicated in pathogenic cartilage
degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS-5 and ADAMTS-4 …
degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS-5 and ADAMTS-4 …
[HTML][HTML] Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
J Larkin, TA Lohr, L Elefante, J Shearin… - Osteoarthritis and …, 2015 - oarsijournal.com
Summary Objective/Method Aggrecanase activity, most notably ADAMTS-5, is implicated in
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …
[引用][C] Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
J Larkin, TA Lohr, L Elefante, J Shearin, R Matico… - Osteoarthritis and …, 2015 - osti.gov
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.
J Larkin, TA Lohr, L Elefante, J Shearin… - Osteoarthritis and …, 2015 - europepmc.org
Results Structural mapping predicts the most potent mAbs employ a unique mode of
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …
inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model …